Stay updated on Pembrolizumab First-line in Advanced Merkel Cell Carcinoma Clinical Trial

Sign up to get notified when there's something new on the Pembrolizumab First-line in Advanced Merkel Cell Carcinoma Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Pembrolizumab First-line in Advanced Merkel Cell Carcinoma Clinical Trial page

  1. Check
    yesterday
    Change Detected
    Summary
    The page now includes a notice about heavy traffic affecting the performance and availability of some NLM-NCBI services and products, along with a contact email for assistance.
    Difference
    1%
    Check dated 2025-02-10T09:31:53.000Z thumbnail image
  2. Check
    8 days ago
    Change Detected
    Summary
    The website has been updated from version 2.14.1 to 2.14.2.
    Difference
    0.1%
    Check dated 2025-02-03T06:16:01.000Z thumbnail image
  3. Check
    15 days ago
    No Change Detected
  4. Check
    22 days ago
    Change Detected
    Summary
    The website has been updated from version 2.14.0 to 2.14.1.
    Difference
    0.1%
    Check dated 2025-01-19T20:14:44.000Z thumbnail image
  5. Check
    30 days ago
    Change Detected
    Summary
    The website has updated the 'type of intervention' feature from version 2.13.3 to 2.14.0, indicating a significant change in this functionality.
    Difference
    0.2%
    Check dated 2025-01-12T17:07:37.000Z thumbnail image
  6. Check
    37 days ago
    Change Detected
    Summary
    The latest update includes detailed definitions and assessments of Duration of Response (DOR), Progression-Free Survival (PFS), and Overall Survival (OS) for participants in the MK-3475-913 study, with a notable increase in the DOR reporting period from approximately 13 years to 58 months, while previous entries have been removed.
    Difference
    3%
    Check dated 2025-01-05T13:55:33.000Z thumbnail image
  7. Check
    59 days ago
    Change Detected
    Summary
    The website has been updated from version 2.13.2 to 2.13.3.
    Difference
    0.1%
    Check dated 2024-12-14T12:25:42.000Z thumbnail image

Stay in the know with updates to Pembrolizumab First-line in Advanced Merkel Cell Carcinoma Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Pembrolizumab First-line in Advanced Merkel Cell Carcinoma Clinical Trial page.